ERBB2 and neoplasm: Median HER2/CEP17 ratio was significantly higher (Wilcoxon, p = 0.005) in tumors with favorable tumor response displaying ratios of 5.54 (2.10–14.30) for RCB 0/I and 4.31 (1.70–9.70) for RCB II/III cases, respectively.